BD (Becton, Dickinson and Company), Franklin Lakes, NJ, received a premarket approval (PMA) supplement from the FDA for an expanded version of its BD Onclarity human papillomavirus (HPV) assay. The PMA supplement includes the expansion for genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66, making the BD Onclarity HPV Assay the only FDA-approved assay to individually identify and report these genotype results.
The value of extended genotyping for cervical cancer screening and triage has been reported from large clinical studies since 2015. Additionally, the need for expanded HPV genotyping for cervical screening has been recognized since 2016. In many cases, the reporting of HPV genotypes with the screening test result could improve risk stratification and support risk-based patient management. The April 2020 publication of the ASCCP risk-based management consensus guidelines anticipated that extended genotyping would be introduced soon.
“BD Onclarity extended genotyping is data-driven precision medicine at its best, helping us effectively and efficiently manage our patients,” says Mark H. Stoler, MD, professor emeritus of pathology, University of Virginia Health System. “Contemporary management of women with abnormal cervical cancer screening results demands an assessment of their risk of precancer. An abundance of recent science clearly shows that knowing the HPV genotype of the patient provides excellent differential stratification of those risks.”
“It is well known that different HPV genotypes carry different risk of cervical cancer, and without the specific knowledge of the HPV genotype in a screening sample many women will be over-treated needlessly,” says Jesper Bonde, PhD, senior researcher and molecular pathology laboratory manager, Hvidovre Hospital, Denmark. “Screening strategies that employ HPV tests with simultaneous genotyping offer a simple way to improve cervical cancer screening to the benefit of the woman and health care providers by allowing risk stratification already on the screening sample.”
The reporting of HPV genotypes with the screening tests and surveillance tests will facilitate same-genotype persistence tracking and risk-based management. A recent systematic review by Bottari et al concluded that, “evaluation of the HPV genotype persistence may represent a valid option to monitor patients treated for CIN 2+ lesions, because relapses were detected only in patients with persistence of the same genotype detected at baseline.”
“With this FDA approval, BD can now offer laboratories, clinicians and patients access to critical information in screening for cervical cancer in the United States and other countries recognizing the PMA supplement or CE mark,” says Dave Hickey, president, integrated diagnostic solutions at BD. “Our goal is to continue the global fight towards eliminating diseases and associated deaths due to cervical cancer with our comprehensive diagnostic solutions.”
For more information, visit BD.